Please login to the form below

Not currently logged in
Email:
Password:

Sanofi and Novartis snap up immuno-oncology candidates

Separate licensing deals see the firms look to catch up with the category's leaders

Sanofi 

Sanofi and Novartis have added to their early-stage cancer immunotherapy pipelines with new licensing deals as they try to catch up with the leaders in the category.

Details of the Novartis agreement are sketchy, but the company says it has licensed four preclinical programmes from Massachusetts-based Surface Oncology's portfolio which target "regulatory T cell populations, inhibitory cytokines, and immunosuppressive metabolites in the tumour microenvironment".

The candidates will be developed as monotherapies as well as in combination with Novartis' own pipeline of immuno-oncology candidates, which includes seven clinical programmes with five more scheduled to start trials this year.

Novartis' immuno-oncology aspirations gathered pace at the start of 2015 when it set up a dedicated R&D team led by cancer vaccine pioneer Glenn Dranoff, and the portfolio is currently led by chimeric antigen receptor T-cell (CART) candidate CTL109 which is in phase II trials for chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and multiple myeloma.

Meanwhile, after some disappointments with in-house R&D, Sanofi's activities in immuno-oncology were kick-started by a $1.8bn alliance with Regeneron and a $1.5bn deal with BioNtech - signed last year alongside smaller deals with Selecta, Evotec and Apeiron Biologics.

Now, the French pharma firm has added a €400m collaboration with Innate Pharma to develop bi-specific (double-headed) antibodies that will target both tumour antigens and NKp46, an activating receptor found on the surface of natural killer (NK) immune cells.

Bi-specific antibodies can be used to bring activated NK cells in close proximity to tumours and encourage them to attack the malignant cells. Under the terms of the agreement with two partners will work on one or two candidates, with Sanofi responsible for development, manufacturing and commercial activities.

Both Novartis and Sanofi have a strong heritage in cancer treatment but have slipped a little behind the leading pack in the emerging immuno-oncology category, which is expected to grow into a market worth tens of billions of dollars a year. 

Currently the market is being led by Bristol-Myers Squibb and Merck & Co - both with already-marketed products - with AstraZeneca (AZ), Roche and Merck KGaA/Pfizer snapping at their heels.

Article by
Phil Taylor

11th January 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four MSA

Four MSA creates world class integrated media solutions with global reach, deep insight, innovative methods and a highly personal approach....

Latest intelligence

Shining our spotlight on… the patient
The second issue of our new SPOTLIGHT ON series is live! In this issue, we discuss the role of patient insights and what impact it has on improving patient outcomes...
Healthcare in the Digital Age
Healthcare is changing. By understanding the needs of the physicians, and using innovative channels to make meaningful connections, pharma can ensure it continues to enjoy a mutually beneficial relationship....
Opinion piece: Patient-centricity and pharma – where are we now?
Patient-centricity is a term that has gained currency in the pharma industry in recent years, and most major companies in the sector are now dedicating resources to ensure that they...

Infographics